Hunan Jiudian Pharmaceutical(300705.SZ): "Alendronate Sodium Oral Solution" Obtained Drug Registration Certificate

Hunan Jiudian Pharmaceutical (300705.SZ) announced that the company has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration. The drug involved is "Oral Solution of Alendronate Sodium". Oral Solution of Alendronate Sodium is used for the treatment of postmenopausal osteoporosis in women, for the prevention of hip and spine fractures (vertebral compression fractures), and for the treatment of male osteoporosis to increase bone mass. Alendronate sodium was first approved for sale in the United States in 1995. Currently, tablets, enteric-coated tablets, and oral solution formulations are marketed and sold domestically and internationally.